{"id":"ab023-dose-1","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PI3K delta, AB023 modulates the immune response and has shown promise in treating various hematological malignancies.","oneSentence":"AB023 is a small molecule that targets the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:21.924Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory chronic lymphocytic leukemia"},{"name":"Relapsed or refractory follicular lymphoma"}]},"trialDetails":[{"nctId":"NCT03612856","phase":"PHASE2","title":"Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis","status":"COMPLETED","sponsor":"Aronora, Inc.","startDate":"2018-10-29","conditions":"End Stage Renal Disease, Thrombosis","enrollment":27},{"nctId":"NCT03097341","phase":"PHASE1","title":"Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Aronora, Inc.","startDate":"2017-06-05","conditions":"Thrombosis","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["xisomab 3G3- Dose 1","xisomab 3G3- Dose 2"],"phase":"phase_2","status":"active","brandName":"AB023- Dose 1","genericName":"AB023- Dose 1","companyName":"Aronora, Inc.","companyId":"aronora-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AB023 is a small molecule that targets the PI3K delta subunit. Used for Relapsed or refractory chronic lymphocytic leukemia, Relapsed or refractory follicular lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}